LENZ Therapeutics (LENZ) Return on Capital Employed (2021 - 2026)
LENZ Therapeutics' (LENZ) quarterly Return on Capital Employed came in at 44.93% in Q1 2026, down 1516.0% year-on-year from 3.17% in Q1 2025, and down 16.89% on a QoQ basis from 38.44% in Q4 2025.
LENZ Therapeutics (LENZ) Return on Capital Employed (2021 - 2026) Analysis & Trends
LENZ Therapeutics (LENZ) has 6 years of Return on Capital Employed data on file, last reported at 44.93% in Q1 2026.
- On a quarterly basis, Return on Capital Employed fell 1516.0% year-over-year to 44.93% in Q1 2026; TTM through Mar 2026 was 44.93%, a 1516.0% decrease from a year earlier, with the FY2025 full-year figure at 38.07%, up 619.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 44.93%, down from 38.44% in the prior quarter.
- Over the last five years, Return on Capital Employed for LENZ reached as high as 20.4% in Q1 2022 and fell as low as 60.74% in Q1 2024.
- Historically, Return on Capital Employed has averaged 34.18% across 5 years, with a median of 31.15% in 2025.
- Across the five-year window, Return on Capital Employed plunged 3014 bps in 2024 and jumped 3097 bps in 2025, its largest moves.
- Year by year, Return on Capital Employed stood at 33.5% in 2022, then tumbled by 44 bps to 48.35% in 2023, then soared by 42 bps to 28.01% in 2024, then sank by 37 bps to 38.44% in 2025, then decreased by 17 bps to 44.93% in 2026.
- Per Business Quant data, the three most recent Return on Capital Employed figures were 44.93% in Q1 2026, 38.44% in Q4 2025, and 34.34% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | LENZ Therapeutics | 158.34 Mn | 158.34 Mn | 825,000.00 | -44.93% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -44.93% |
| Dec 31, 2025 | -38.44% |
| Sep 30, 2025 | -34.34% |
| Jun 30, 2025 | -31.15% |
| Mar 31, 2025 | -29.77% |
| Dec 31, 2024 | -28.01% |
| Sep 30, 2024 | -33.25% |
| Jun 30, 2024 | -37.39% |
| Mar 31, 2024 | -60.74% |
| Dec 31, 2023 | -48.35% |
| Sep 30, 2023 | -28.09% |
| Jun 30, 2023 | -28.12% |
| Mar 31, 2023 | -30.60% |
| Dec 31, 2022 | -33.50% |
| Sep 30, 2022 | -29.57% |
| Jun 30, 2022 | -24.36% |
| Mar 31, 2022 | -20.40% |
| Dec 31, 2021 | -15.23% |
| Sep 30, 2021 | -12.76% |